Asset
NEZULCITINIB
Theravance Biopharma Inc. Ordinary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04350736 | phase1 | completed | 2020-04-23 | 2020-06-24 | Theravance Biopharma | First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19 |
| NCT04402866 | phase2 | completed | 2020-06-24 | 2021-04-21 | Theravance Biopharma | TD-0903 for ALI Associated With COVID-19 |
FDA applications (0)
This company has no applications containing this asset.